Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
August 17, 2018updated 12 Aug 2019 10:38am

Deals and M&As this week: Aridis Pharmaceuticals, Xeris Pharmaceuticals, Astellas Pharma

Deals and M&As this week: Aridis Pharmaceuticals, Xeris Pharmaceuticals, Astellas Pharma

Aridis Pharmaceuticals has raised $26m through an initial public offering of two million shares of its common stock priced at $13 a share.

The underwriters will have a 30-day option to buy an additional 0.3 million shares of the company’s common stock.

Based in the US, Aridis is a biopharmaceutical company focused on the development of innovative therapies for infectious diseases.

Maxim Group has been appointed as the lead manager, while Laidlaw & Company (UK), Northland Securities and Seaport Global Securities are acting as co-managers to Aridis for the offering.

Xeris Pharmaceuticals has raised $98.3m through an initial public offering of 6.5 million shares of its common stock priced at $15 a share.

The underwriters will have a 30-day option to buy an additional 0.85 million shares of the company’s common stock.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Based in the US, Xeris is a speciality pharmaceutical company engaged in the development and commercialisation of room-temperature stable injectable and infusible drug formulations.

Jefferies, Leerink Partners, RBC Capital Markets and Mizuho Securities were appointed as the joint book running managers to the company for the offering.

Astellas Pharma has completed the acquisition of UK-based gene therapy company Quethera for $108.5m.

Quethera will receive £85m ($108.5m) in upfront and contingent payments from Astellas, as part of the transaction.

“Xeris Pharmaceuticals has raised $98.3m through an initial public offering of 6.5 million shares of its common stock priced at $15 a share.”

The acquisition includes Quethera’s ophthalmic gene therapy programme, which will be a complementary addition to Astellas’ portfolio.

Based in Japan, Astellas is a pharmaceutical company offering products for several therapeutic areas such as cardiology, dermatology, oncology, and urology.

The deal enables the acquirer company to accelerate the development of investigational technology programme to prevent disease progression in patients suffering from serious diseases.

Emergent BioSolutions has entered an agreement to acquire PaxVax for $270m in cash.

The transaction includes US FDA licensed Vivotif vaccine indicated for the treatment of typhoid fever, and Vaxchora, a vaccine used for the prevention of cholera. In addition, the purchase includes the target company’s European biologics manufacturing.

Based in the US, Emergent BioSolutions is engaged in the development and commercialisation of immunobiotics such as vaccines and immune globulins, while PaxVax, also based in the US, is a manufacturer of vaccines for various infectious diseases.

The transaction will enable Emergent BioSolutions to diversify its customer base and international reach and boost its contract development and manufacturing capabilities.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU